1. Cheung, N. K., Kushner, B. H., LaQuaglia, M., and Lindsley, K. (1997) Treatment of advanced stage neuroblastoma, in Principles and Practice of Genitourinary Oncology ( Reghavan, D., Scher, H. I., Leibel, S. A., and Lange, P., eds.), J.B. Lippincott, Philadelphia, pp. 1101–1111.
2. Brodeur, G. M. and Castleberry, R. P. (1997) Neuroblastoma, in Principles and Practice of Pediatric Oncology (Pizzo, P. A. and Poplack, D. G., eds.), 3rd ed., J.B. Lippincott, Philadelphia, pp. 761–797.
3. Wikstrand, C. J., Fredman, P., Svennerholm, L., Humphrey, P. A., Bigner, S. H., and Bigner, D. D. (1992) Monoclonal antibodies to malignant human gliomas. Mol. Chem. Neuropathol. 17, 137–146.
4. Livingston, P.O., Wong, G. Y. C., Adluri, S., Tao, Y., Padavan, M., Parente, R., et al. (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12, 1036–1044.
5. Morton, D. L., Ravindranath, M. H., and Irie, R. F. (1994) Tumor gangliosides as targets for active specific immunotherapy of melanoma in man, in Progress in Brain Research (Svennerholm, L., Asbury, A., Reisfeld, R. A., Sandhoff, K., Suzuki, K., Tettamanti, G., and Toffano, G., eds.), Vol. 101, Elsevier, pp. 251–275.